Evidence map›Paper›PMID 38925248›Full record

ArticleMolecular metabolism2024

Muscle weakness and mitochondrial stress occur before severe metastasis in a novel mouse model of ovarian cancer cachexia.

Luca J Delfinis, Leslie M Ogilvie, Shahrzad Khajehzadehshoushtar, Shivam Gandhi, Madison C Garibotti, Arshdeep K Thuhan, Kathy Matuszewska, Madison Pereira, Ronald G Jones, Arthur J Cheng and 6 more

Abstract read
In one paragraph

Article in Molecular metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. GL261 glioblastoma induces delayed body weight gain and stunted skeletal muscle growth in young mice.American journal of physiology. Regulatory, integrative and comparative physiology · 2025
    Article
  7. Article
  8. Exploring heterogeneity: a dive into preclinical models of cancer cachexia.American journal of physiology. Cell physiology · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Luca J DelfinisSchool of Kinesiology & Health Science, Muscle Health Research Centre, York University, Toronto, ON, Canada. Electronic address: delfinis@yorku.ca.
Leslie M OgilvieDepartment of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON, Canada. Electronic address: ogilviel@uoguelph.ca.
Shahrzad KhajehzadehshoushtarSchool of Kinesiology & Health Science, Muscle Health Research Centre, York University, Toronto, ON, Canada. Electronic address: shar99@yorku.ca.
Shivam GandhiSchool of Kinesiology & Health Science, Muscle Health Research Centre, York University, Toronto, ON, Canada. Electronic address: shivamg@yorku.ca.
Madison C GaribottiSchool of Kinesiology & Health Science, Muscle Health Research Centre, York University, Toronto, ON, Canada. Electronic address: mgarib@yorku.ca.
Arshdeep K ThuhanSchool of Kinesiology & Health Science, Muscle Health Research Centre, York University, Toronto, ON, Canada. Electronic address: thuhan@yorku.ca.
Kathy MatuszewskaDepartment of Biomedical Sciences, University of Guelph, Guelph, ON, Canada. Electronic address: kmatusze@uoguelph.ca.
Madison PereiraDepartment of Biomedical Sciences, University of Guelph, Guelph, ON, Canada. Electronic address: mperei02@uguelph.ca.
Ronald G JonesExercise Science Research Center, Department of Health, Human Performance, and Recreation, University of Arkansas, Fayetteville, AR, USA. Electronic address: ronaldj@uark.edu.
Arthur J ChengSchool of Kinesiology & Health Science, Muscle Health Research Centre, York University, Toronto, ON, Canada. Electronic address: ajcheng@yorku.ca.
Thomas J HawkeDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada. Electronic address: hawke@mcmaster.ca.
Nicholas P GreeneExercise Science Research Center, Department of Health, Human Performance, and Recreation, University of Arkansas, Fayetteville, AR, USA. Electronic address: npgreene@uark.edu.
Kevin A MurachExercise Science Research Center, Department of Health, Human Performance, and Recreation, University of Arkansas, Fayetteville, AR, USA. Electronic address: kmurach@uark.edu.
Jeremy A SimpsonDepartment of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON, Canada. Electronic address: jeremys@uoguelph.ca.
Jim PetrikDepartment of Biomedical Sciences, University of Guelph, Guelph, ON, Canada. Electronic address: jpetrik@uoguelph.ca.
Christopher G R PerrySchool of Kinesiology & Health Science, Muscle Health Research Centre, York University, Toronto, ON, Canada. Electronic address: cperry@yorku.ca.

Funding

DEVELOPMENT OF TARGETED APPROACHES IN PREVENTION OF CANCER-CACHEXIAR01AR075794 · NIAMS · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI GREENE, NICHOLAS PERRY · 2020 to 2024
$1.6M
NIAMS NIH HHS R01 AR075794
6 · The paper itself

Abstract

objectivesA high proportion of women with advanced epithelial ovarian cancer (EOC) experience weakness and cachexia. This relationship is associated with increased morbidity and mortality. EOC is the most lethal gynecological cancer, yet no preclinical cachexia model has demonstrated the combined hallmark features of metastasis, ascites development, muscle loss and weakness in adult immunocompetent mice.

methodsHere, we evaluated a new model of ovarian cancer-induced cachexia with the advantages of inducing cancer in adult immunocompetent C57BL/6J mice through orthotopic injections of EOC cells in the ovarian bursa. We characterized the development of metastasis, ascites, muscle atrophy, muscle weakness, markers of inflammation, and mitochondrial stress in the tibialis anterior (TA) and diaphragm ∼45, ∼75 and ∼90 days after EOC injection.

resultsPrimary ovarian tumour sizes were progressively larger at each time point while severe metastasis, ascites development, and reductions in body, fat and muscle weights occurred by 90 Days. There were no changes in certain inflammatory (TNFα), atrogene (MURF1 and Atrogin) or GDF15 markers within both muscles whereas IL-6 was increased at 45 and 90 Day groups in the diaphragm. TA weakness in 45 Day preceded atrophy and metastasis that were observed later (75 and 90 Day, respectively). The diaphragm demonstrated both weakness and atrophy in 45 Day. In both muscles, this pre-severe-metastatic muscle weakness corresponded with considerable reprogramming of gene pathways related to mitochondrial bioenergetics as well as reduced functional measures of mitochondrial pyruvate oxidation and creatine-dependent ADP/ATP cycling as well as increased reactive oxygen species emission (hydrogen peroxide). Remarkably, muscle force per unit mass at 90 days was partially restored in the TA despite the presence of atrophy and severe metastasis. In contrast, the diaphragm demonstrated progressive weakness. At this advanced stage, mitochondrial pyruvate oxidation in both muscles exceeded control mice suggesting an apparent metabolic super-compensation corresponding with restored indices of creatine-dependent adenylate cycling.

conclusionsThis mouse model demonstrates the concurrent development of cachexia and metastasis that occurs in women with EOC. The model provides physiologically relevant advantages of inducing tumour development within the ovarian bursa in immunocompetent adult mice. Moreover, the model reveals that muscle weakness in both TA and diaphragm precedes severe metastasis while weakness also precedes atrophy in the TA. An underlying mitochondrial bioenergetic stress corresponded with this early weakness. Collectively, these discoveries can direct new research towards the development of therapies that target pre-atrophy and pre-severe-metastatic weakness during EOC in addition to therapies targeting cachexia.

Indexed as

CachexiaDisease Models, AnimalMice, Inbred C57BLMitochondriaMuscle WeaknessOvarian NeoplasmsAnimalsCarcinoma, Ovarian EpithelialCell Line, TumorFemaleMiceMuscle, SkeletalMuscular AtrophyNeoplasm MetastasisMetastasisMitochondriaOvarian cancer cachexiaSkeletal muscle

Identifiers

PMID38925248
PMCPMC11278933

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.